April 09, 2019
Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases
– Funding will
“It takes more than medicine alone to improve the lives of people living
with liver diseases. In HCV, understanding optimal ways to simplify
testing and treatment is critical to reaching diverse populations living
with the disease. People living with NASH need to access earlier
diagnoses and clearer referral pathways to help them access care,” said
The new grant programs are:
- HCV STAT (Simplification and Test
Strategies toward HCV Elimination)
This program will fund approximately fifteen projects with a total commitment of US
$10Mfocused on simplifying HCV care delivery and implementing test and treat strategies to overcome barriers to patient care. Applications will be accepted from April 11 to June 30, 2019.
STAT is the latest addition to the LEGA-C platform, “Local Elimination Programs Leading to Global Action in HCV” and includes the ongoing programs CITE, SCALE, CHIME, and NoCo. To date, Gilead has committed
$50Mto support 79 elimination projects around the world through LEGA-C.
- HIV/HCV NoCo (NoCo-Infection)
In the third installment of NoCo, this program will fund approximately six to eight projects with a total commitment of US
$3Mfocused on investigating strategies to link patients living with HCV and HIV co-infection to HCV treatment. Applications will be accepted from May 1 to June 14, 2019.
- NASH Models of Care
This program will fund approximately eight to ten projects with a total commitment of US
$4Mfocused on investigating care pathways between multidisciplinary providers for screening, identifying, and helping to refer high-risk patients living with NASH to appropriate medical care. Applications will be accepted from June 3 to July 15, 2019.
- HBV CARE (Linkage to CARe & Epidemiology
in Special Populations)
This program will fund approximately six projects with a total commitment of US
$1Mfocused onimproving linkage to care among underserved population andanalyzingor identifying data gaps inHBV epidemiology in specific demographics or geographies. Applications will be accepted from August 1 to September 15, 2019.
- PSC PACE (PrimAry
Sclerosing Cholangitis Epidemiology)
This program will fund up to five projects with a total commitment of US
$1Mfocused on identifying gaps in PSC epidemiology data and improving understanding of the cascade of care. Applications will be accepted from September 16 to October 11, 2019.
For more information on Gilead’s new liver disease grants programs, please visit https://www.gilead.com/science-and-medicine/research/investigator-sponsored-research.
For more information on
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005654/en/
Sung Lee, Investors
Arran Attridge, Media